Clinical Features and Outcomes of Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid (DPP4i-Associated BP) in Thai Patients

The use of dipeptidyl peptidase-4 inhibitors (DPP4i) appears to be associated with a small but significantly elevated risk of bullous pemphigoid (BP). Although the pathogenic mechanism of DPP4i-associated BP remains unclear, this adverse event is reported with multiple gliptins, suggesting a class e...

Descripción completa

Detalles Bibliográficos
Autores principales: Thewjitcharoen, Yotsapon, Wanothayaroj, Ekgaluck, Thammawiwat, Chattip, Porramatikul, Sriurai, Vorayingyong, Chuleekorn, Nakasatien, Soontaree, Krittiyawong, Sirinate, Chanprapaph, Kumutnart, Himathongkam, Thep
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7569454/
https://www.ncbi.nlm.nih.gov/pubmed/33101737
http://dx.doi.org/10.1155/2020/8832643

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7569454/
https://www.ncbi.nlm.nih.gov/pubmed/33101737
http://dx.doi.org/10.1155/2020/8832643

Ejemplares similares